The core activity of metaLead Therapeutics AG is the development of innovative, safe and effective medicines for the treatment of diseases caused by the accumulation of heavy metals such as lead, mercury and copper. The company focuses particularly on the development of chelation therapies that specifically target certain heavy metals and can remove them from the body without affecting essential metals. The company's products aim to revolutionize the treatment of diseases such as lead poisoning and Wilson's disease, and improve the quality of life for patients.